284 related articles for article (PubMed ID: 1826520)
21. Preservation of 5-hydroxytryptamine1A receptor-G protein interactions in the cerebral cortex of patients with Alzheimer's disease.
O'Neill C; Cowburn RF; Wiehager B; Alafuzoff I; Winblad B; Fowler CJ
Neurosci Lett; 1991 Nov; 133(1):15-9. PubMed ID: 1838799
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a novel serotonin receptor subtype (5-HT1S) in rat CNS: interaction with a GTP binding protein.
Zemlan FP; Schwab EF
J Neurochem; 1991 Dec; 57(6):2092-9. PubMed ID: 1834802
[TBL] [Abstract][Full Text] [Related]
23. Characterisation of the binding of [3H]WAY-100635, a novel 5-hydroxytryptamine1A receptor antagonist, to rat brain.
Khawaja X; Evans N; Reilly Y; Ennis C; Minchin MC
J Neurochem; 1995 Jun; 64(6):2716-26. PubMed ID: 7760052
[TBL] [Abstract][Full Text] [Related]
24. Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist.
Jerning E; Svantesson GT; Mohell N
Eur J Pharmacol; 1998 Nov; 360(2-3):219-25. PubMed ID: 9851589
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological characterization of recombinant human 5-hydroxytryptamine1A receptors using a novel antagonist radioligand, [3H]WAY-100635.
Khawaja X; Ennis C; Minchin MC
Life Sci; 1997; 60(9):653-65. PubMed ID: 9048968
[TBL] [Abstract][Full Text] [Related]
26. 2-(Alkylamino)tetralin derivatives: interaction with 5-HT1A serotonin binding sites.
Naiman N; Lyon RA; Bullock AE; Rydelek LT; Titeler M; Glennon RA
J Med Chem; 1989 Jan; 32(1):253-6. PubMed ID: 2521252
[TBL] [Abstract][Full Text] [Related]
27. Lack of apparent receptor reserve at postsynaptic 5-hydroxytryptamine1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes.
Yocca FD; Iben L; Meller E
Mol Pharmacol; 1992 Jun; 41(6):1066-72. PubMed ID: 1352034
[TBL] [Abstract][Full Text] [Related]
28. [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia.
Burnet PW; Eastwood SL; Harrison PJ
Neurochem Int; 1997 Jun; 30(6):565-74. PubMed ID: 9152998
[TBL] [Abstract][Full Text] [Related]
29. Pharmacology of [3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen.
Hillefors M; von Euler G
Neurochem Int; 2001 Jan; 38(1):31-42. PubMed ID: 10913686
[TBL] [Abstract][Full Text] [Related]
30. [3H]spiroxatrine labels a serotonin1A-like site in the rat hippocampus.
Nelson DL; Monroe PJ; Lambert G; Yamamura HI
Life Sci; 1987 Sep; 41(13):1567-76. PubMed ID: 2957559
[TBL] [Abstract][Full Text] [Related]
31. [3H]8-OH-DPAT labels the 5-hydroxytryptamine uptake recognition site and the 5-HT1A binding site in the rat striatum.
Alexander BS; Wood MD
J Pharm Pharmacol; 1988 Dec; 40(12):888-91. PubMed ID: 2907586
[TBL] [Abstract][Full Text] [Related]
32. Further characterisation of [3H]8-hydroxy-2-(di-N-propylamino)tetralin binding sites in human brain postmortem.
Palego L; Marazziti D; Rotondo A; Batistini A; Lucacchini A; Naccarato AG; Bevilacqua G; Borsini F; Ladinsky H; Cassano GB
Neurochem Int; 1997 Feb; 30(2):149-57. PubMed ID: 9017662
[TBL] [Abstract][Full Text] [Related]
33. Potency of 5-hydroxytryptamine1a agonists to inhibit adenylyl cyclase activity is a function of affinity for the "low-affinity" state of [3H]8-hydroxy-N,N-dipropylaminotetralin ([3H]8-OH-DPAT) binding.
Chamberlain J; Offord SJ; Wolfe BB; Tyau LS; Wang HL; Frazer A
J Pharmacol Exp Ther; 1993 Aug; 266(2):618-25. PubMed ID: 8355195
[TBL] [Abstract][Full Text] [Related]
34. Hippocampal 8-[3H]hydroxy-2-(di-n-propylamino) tetralin binding site densities, serotonin receptor (5-HT1A) messenger ribonucleic acid abundance, and serotonin levels parallel the activity of the hypothalamopituitary-adrenal axis in rat.
Burnet PW; Mefford IN; Smith CC; Gold PW; Sternberg EM
J Neurochem; 1992 Sep; 59(3):1062-70. PubMed ID: 1379629
[TBL] [Abstract][Full Text] [Related]
35. [3H]Alnespirone: a novel specific radioligand of 5-HT1A receptors in the rat brain.
Fabre V; Boni C; Mocaër E; Lesourd M; Hamon M; Laporte AM
Eur J Pharmacol; 1997 Oct; 337(2-3):297-308. PubMed ID: 9430429
[TBL] [Abstract][Full Text] [Related]
36. Antagonism of 5-hydroxytryptamine1A (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers.
Oksenberg D; Peroutka SJ
Biochem Pharmacol; 1988 Sep; 37(18):3429-33. PubMed ID: 2971358
[TBL] [Abstract][Full Text] [Related]
37. Differential sensitivity of 3H-agonist binding to pre- and postsynaptic 5-HT1A receptors in bovine brain.
Iben LG; Mahle CD; Yocca FD
Br J Pharmacol; 1994 Dec; 113(4):1400-6. PubMed ID: 7889298
[TBL] [Abstract][Full Text] [Related]
38. Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats.
Lejeune F; Newman-Tancredi A; Audinot V; Millan MJ
J Pharmacol Exp Ther; 1997 Mar; 280(3):1241-9. PubMed ID: 9067310
[TBL] [Abstract][Full Text] [Related]
39. Irreversible blockade of central 5-HT1A receptor binding sites by the photoaffinity probe 8-methoxy-3'-NAP-amino-PAT.
Emerit MB; Gozlan H; Marquet A; Hamon M
Eur J Pharmacol; 1986 Aug; 127(1-2):67-81. PubMed ID: 2944752
[TBL] [Abstract][Full Text] [Related]
40. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin.
Hoyer D; Engel G; Kalkman HO
Eur J Pharmacol; 1985 Nov; 118(1-2):13-23. PubMed ID: 2935410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
